What Investors Look For in Public Health-Tech Companies

Hillary Remy

on December 10, 2025

Hillary Remy

on December 10, 2025

Written by Hillary Remy

Edited by Omobolade Ajibade

What Investors Look For in Public Health-Tech Companies

Key Takeaways

Revenue growth trajectory and path to profitability remain critical, with the medtech industry reaching $584 billion in 2025 and posting consistent 6 to 7% growth
FDA approvals and regulatory milestones serve as major catalysts, with 136 breakthrough device designations granted in fiscal 2025 through June
Strategic partnerships and acquisitions surged in 2025, with average deal sizes reaching $497 million, up 11% from 2024
Clinical safety data and robust trial outcomes are essential for securing investment, particularly as early stage funding rebounds
Technological innovation, especially AI integration, commands premium valuations with medical device AI spending hitting $2.4 billion in 2025

As 2025 draws to a close, the health technology sector has demonstrated remarkable resilience and growth, emerging as one of the most compelling investment opportunities of the year. For investors evaluating public medtech companies, understanding the key metrics and milestones that drive success has become increasingly critical. The sector has rebounded strongly from the challenging post pandemic years, with venture capital and M&A activity reaching levels not seen in over a decade.

Revenue Growth and Financial Performance

Strong revenue growth paired with improving operational efficiency remains the foundation of investor confidence in medtech companies. The global medtech industry reached $584 billion in 2025, with commercial leaders on track to record 6% to 7% revenue growth for the seventh consecutive year despite macroeconomic headwinds and trade uncertainty.

The investment landscape has shifted toward quality over quantity. Medtech private investment has become increasingly polarized, as record funding for scaled platforms comes at the expense of early stage innovation, according to PitchBook’s Q3 2025 analysis. This polarization reflects investor preference for companies demonstrating not just top line growth, but sustainable paths to profitability with strong unit economics.

Q1 2025 saw record breaking medical device venture funding, with $2.6 billion raised across 132 deals, signaling robust investor appetite for well positioned companies. The structure of these investments reveals a clear trend: larger rounds, expanded syndicates, and shared risk among multiple investors seeking to back companies with proven commercial traction.

Companies that can demonstrate consistent revenue expansion while maintaining or improving margins command premium valuations. The market particularly rewards businesses targeting large addressable markets with scalable solutions that address significant unmet medical needs, especially in high growth therapeutic areas like cardiovascular devices, orthopedics, and in vitro diagnostics.

FDA Approvals and Regulatory Milestones

Regulatory clearances function as transformative inflection points that can dramatically alter company trajectories and valuations. In fiscal 2025, which began in October 2024, the FDA granted 136 breakthrough device designations as of June 30, demonstrating continued regulatory support for innovative technologies addressing life threatening or debilitating conditions.

The FDA’s breakthrough device program has become particularly important to investors, as products receiving this designation gain expedited review and, increasingly, faster paths to Medicare coverage. A total of 1,176 products have received breakthrough designation since the program’s inception in 2015, providing a clear runway for companies to accelerate commercialization.

The FDA has recently authorized over 100 AI enabled medical devices across radiology, cardiology, neurology, and reproductive medicine applications in 2025, reflecting the agency’s embrace of machine learning and software based diagnostics. This regulatory openness to AI integration has created significant opportunities for companies developing next generation diagnostic and therapeutic tools.

Recent FDA approvals underscore the value of well executed regulatory strategies. Abbott’s Volt pulsed field ablation system received FDA approval December 22, 2025, joining an intensifying competitive landscape that includes Medtronic, Boston Scientific, and Johnson & Johnson. These approvals in hot therapeutic areas like cardiac ablation often trigger substantial stock price movements and renewed investor interest.

Investors increasingly scrutinize companies’ regulatory roadmaps during due diligence. Clearly defined pathways through 510(k) clearance, justified De Novo classification, or comprehensive PMA submissions signal management sophistication. Companies that engage proactively with the FDA through pre submission processes demonstrate risk management capabilities that instill confidence in potential backers.

Strategic Partnerships and M&A Activity

Strategic partnerships serve dual functions: validating technology credibility and creating clear paths to liquidity events. M&A deal values in 2025 totaled $38.8 billion, with the average deal size reaching $497 million, up 11% from 2024 and 72% higher than the previous decade’s average. This shift toward fewer but larger transactions reflects strategic buyers seeking high impact acquisitions.

After a slowdown in 2022 and 2023, notable increases in buy side M&A activity emerged in 2024 and continued through 2025, driven by favorable macroeconomic conditions and substantial cash reserves that major medtech companies accumulated through recent divestitures. Companies are actively searching for innovative pre commercial companies in high growth markets and therapeutic areas.

The trend toward strategic partnerships has accelerated. In Q3 2025, the medtech sector saw 21 licensing partnerships valued at $7.9 billion total, with over $126 million in upfront payments, according to J.P. Morgan analysis. These arrangements provide crucial commercial validation without requiring full integration, often serving as stepping stones to deeper strategic relationships or eventual acquisitions.

Investors view partnerships with established healthcare giants like Medtronic, Boston Scientific, or Johnson & Johnson as powerful de risking mechanisms. When these industry leaders invest in or partner with emerging medtech firms, it signals third party validation of the technology’s commercial potential and often leads to acquisition discussions that provide clear exit opportunities for venture investors.

The build to buy model has gained particular traction, where strategic medtech companies partner early with startups, investing capital while retaining acquisition options if milestones are met. This approach offers emerging companies crucial resources and defined paths to acquisition, while strategic investors can observe performance before committing to full buyouts.

Clinical Safety Track Record

Comprehensive clinical evidence demonstrating both safety and efficacy forms the bedrock of investor confidence. The quality of clinical trial design, including thoughtfully crafted protocols and appropriate patient selection criteria, directly impacts investor perception of a company’s execution capabilities.

For pre commercial companies, preliminary clinical data confirming safety and feasibility can be transformative for fundraising. Companies that successfully demonstrate positive safety profiles and meaningful clinical benefits in well designed studies position themselves to attract significant capital, even for the expensive pivotal trial phase.

Public markets have reemerged as the medtech sector’s main exit engine, with a wave of IPOs offsetting muted M&A activity in certain segments. Companies with strong clinical safety track records and compelling efficacy data have successfully accessed public markets in 2025, with HeartFlow’s $364 million IPO in August serving as a prominent example of market appetite for clinically validated technologies.

Investors increasingly fund technologies requiring large clinical trials when growth potential justifies the investment. The willingness to support pivotal trial rounds has notably improved in 2025, with many investors now comfortable backing companies through capital intensive late stage development if clinical data supports the investment thesis.

Technologies demonstrating consistent safety across multiple trial phases also benefit from reduced regulatory risk. Products with strong safety records face fewer hurdles obtaining broader approvals or expanding into adjacent indications, multiplying their commercial potential and attractiveness to investors seeking scalable opportunities.

Technological Innovation and Market Positioning

Innovation drives medtech investment, particularly in areas demonstrating transformative potential. Medical device companies’ spending on AI reached $2.4 billion in 2025, with projections suggesting AI applications in healthcare will reach $19 billion by 2027. Investors recognize AI’s potential to make devices smarter, more personalized, and more effective, driving premium valuations for companies successfully integrating these capabilities.

Medtech companies have been rapidly adopting cutting edge technologies including wearables, connected care platforms, and generative AI based solutions, which are expected to transform the sector and improve patient outcomes. These innovations promise to revolutionize healthcare delivery, reduce costs, and address critical workforce shortages simultaneously.

The emergence of AI enabled diagnostics has attracted particularly intense investor interest. Companies developing AI powered tools for radiology, cardiology, and pathology applications have secured substantial funding rounds. HeartFlow’s successful IPO demonstrates market appetite for AI driven diagnostics that directly tie to measurable clinical and economic endpoints, such as reducing unnecessary invasive procedures.

Market positioning significantly influences investor decisions regarding competitive dynamics. Companies addressing large unmet needs in growing therapeutic areas command attention, particularly those able to demonstrate differentiated value propositions and sustainable competitive advantages. Technologies positioned to benefit from broader healthcare trends, such as solutions enabling care delivery outside traditional hospital settings or improving health economics, resonate strongly with forward looking investors.

Global medtech VC hit $4.1 billion in Q1 2025, with investment priorities shifting toward startups demonstrating proven clinical validation, clear regulatory pathways, and scalable adoption metrics. This evolution reflects a more mature investment landscape where evidence based decision making has replaced hype driven capital deployment.

Conclusion

As 2025 concludes, successful medtech companies attracting substantial investor capital demonstrate excellence across multiple interconnected dimensions. Strong revenue growth combined with improving margins signals financial health and operational discipline. FDA approvals and well executed regulatory strategies reduce risk and accelerate commercialization timelines. Strategic partnerships validate technology and create acquisition pathways that provide investor liquidity. Robust clinical safety data builds confidence in both efficacy and regulatory prospects. Finally, genuine innovation addressing substantial unmet needs in growing markets positions companies for sustainable competitive advantage.

The medtech investment landscape has matured significantly through 2025, with investors exhibiting greater sophistication in evaluating opportunities. The polarization between early stage and late stage funding reflects a market demanding proof points before committing capital at scale. For companies seeking investment, excelling across revenue growth, regulatory achievement, partnership development, clinical validation, and technological innovation provides the strongest foundation for attracting capital and achieving long term success.

Looking ahead to 2026, these fundamental metrics will continue guiding investment decisions as the sector navigates ongoing regulatory changes, technological advancement, and evolving healthcare delivery models. Companies demonstrating clear competitive advantages backed by solid evidence across these key areas will be best positioned to thrive in this dynamic and high potential sector.